Vitiligo Vulgaris
Conditions
Brief summary
Patients with stable vitiligo with 2 or more symmetric patches, 2 on acral sites and/or 2 on non acral sites will be recruited and assessed for eligibility for inclusion to receive NB-UVB on the whole body, and carboxytherapy on one randomized side.
Interventions
DEVICENB-UVB alone
Narrow-Band Ultraviolet B phototherapy full cabin
DEVICENB-UVB combined with carboxy
Narrow-Band Ultraviolet B phototherapy full cabin combined with Intradermal injection of carbon dioxide gas
Sponsors
Kasr El Aini Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with stable non-segmental vitiligo (≥2 symmetrical patches of diameter less than 2 cm on acral or ≥ 2 symmetrical patches on non-acral sites). Subjects were stable for twelve or more months.
Exclusion criteria
* Subjects with unstable vitiligo. * Subjects with segmental vitiligo. * Pregnant females. * Severe anemia (Hb \<7 gm/dl). * Cardiac/hepatic/renal/respiratory failure. * Superficial thrombophlebitis. * Subjects with history of skin malignancy or precancerous conditions like Xeroderma pigmentosum. * Subjects with other autoimmune disorders. * Systemic drugs for vitiligo in the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vitiligo Extent Score for a Target Area (VESTA) | 6 months- 1 year | Assessment of the treatment response in a target area Range 0-100% |
| Estimation of human E-Cadherin using ELISA | 6 months -1 year | — |
| Estimation of malondialdehyde by spectrophotometer | 6 months-1 year | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients' global satisfaction | 6 months -1 year | five-point grading scale -1-3 |
Countries
Egypt
Outcome results
None listed